You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三葉草生物-B(02197.HK)擬配售1.28億股淨籌約5億港元
格隆匯 12-06 08:16

格隆匯12月6日丨三葉草生物-B(02197.HK)發佈公吿,2022年12月6日(交易時段前),公司及配售代理瑞信訂立配售協議,據此,配售代理已同意擔任公司代理,根據配售協議所載條款及在其條件規限下盡力促使認購人以配售價認購合共1.28億股配售股份,配售價為每股3.95港元。

該配售股份相當於公司截至該公吿日期已發行股本約11.00%及經配發及發行配售股份擴大後已發行股本約9.91%。經扣除相關費用及開支後,公司將自配售事項收取的所得款項淨額估計約為5.005億港元。配售事項會加強公司財務狀況及促進未來發展,亦會擴闊公司股東基礎及提升股份流通性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account